Background: Metabolic Syndrome (MetS) is associated with elevated risk of diabetes, cardiovascular disease, and premature mortality. To date, however, the association between MetS and obesity-related cancers has not been systematically assessed within a population-based sample.
Introduction
Metabolic syndrome (MetS) currently affects approximately onethird of U.S. adults, and is disproportionately experienced by older individuals, women, and those with excess weight [1, 2] . Obesity, as a central component of MetS, is also associated with oxidative stress, which is on the causal pathway of several age-related diseases, including cardiovascular disease, diabetes and cancer [3, 4] . Because aging is associated with increased oxidative stress and inflammation, free radical and immunological theories suggest a relationship between MetS and several types of cancer [5] [6] [7] . Although the relationships between MetS, obesity, and cancer survival are complex, a protective effect of physical activity and low sedentary behaviour and cancer has been demonstrated [8] .
In a recent meta-analysis, men with MetS had a greater relative risk of liver (43%), colorectal (25%), and bladder (10%) cancers, but decreased prostate cancer risk (29%) compared to those without MetS. In the same study, women with MetS had increased pancreatic (58%), postmenopausal breast (56%), colorectal (34%) and endometrial (61%) cancer risk [9] . Reviews that have focused on individual MetS components (e.g. "overt diabetes", "pre-eclampsia" and obesity) have reported mixed results, and may be accounted for in part due to variation in study design, MetS criteria, and population of interest [10] [11] [12] [13] [14] [15] [16] . Similarly, a number of cohort and case-control studies have also assessed whether cancer risk varies according to the number of MetS components, yielding inconsistent results [17] [18] [19] [20] [21] [22] . As with the studies of MetS overall, these investigations have largely focused on a select group of cancers, and none have explored the association within nationally representative data that allows for generalization to a geographically and demographically diverse sample of the U.S. population.
The purpose of this study was to therefore quantify the association between MetS (overall, number, and individual components), and any-site, breast, prostate and colon cancers in multiple cycles of the U.S. National Health and Nutrition Examination Survey (NHANES).
Methods

Participants
The U.S. NHANES was designed to assess the health and nutritional status of adults and children in the United States, details of which can be found elsewhere [1, 8] educational attainment and income, and were more likely to be non-Hispanic white. The frequency of any-site, breast, prostate and colon cancers were also higher in the MetS vs. non-MetS groups (740 vs. 556, 109 vs. 72, 124 vs. 80, and 65 vs. 30, respectively). On the other hand, adults without MetS were more likely to engage in "recreational/" to be consistent 'recreational/leisure-time' , house/yard work-, and transportrelated physical activity. Prevalence's of past or current smoking, ≥3 alcohols drinks/day, normal weight and overweight individuals were also significantly higher in the non-MetS group. Figure 1 shows the distribution of the number of MetS components and MetS in the U.S. adult population. Overall, the prevalence of MetS was 38.1 ± 0.7% [≤ 50 years: 26.0 ± 0.7% vs. > 50 years: 56.4 ± 0.9%, p <0.0001], with no significant sex difference [M: 38.2 ± 0.8%; F: 37.9 ± 0.9%]. mmol/L (mM); HDL-cholesterol < 1.04 nM (men), 1.29 mM (women); blood pressure (BP ≥ 130/85 mmHg of either diastolic or systolic pressures; and fasting plasma glucose ≥ 5.6 mM [23] . Participants who self-reported the use of medications for blood pressure, cholesterol, or diabetes were identified as having high blood pressure, dyslipidaemia, and high fasting glucose, respectively.
Cancer
Cancer history (yes/no) was based on a single-item self-report ('has a physician or health professional ever told you that you have a cancer or malignancy of any kind'?). Participants who responded 'yes' were then asked to report the specific type of cancer.
Covariates
On the basis of previous literature, the following were included as covariates in our analyses [24] . Total physical activity level was based on physical activity due to house/yard work, transportation and recreational/leisure-time activities. Physical activity was quantified in Metabolic Equivalent (MET) min/week from self-reported physical activity data. To calculate MET min/week, moderate and vigorous activities were assumed to have 4 MET and 8 MET energy expenditure values, respectively [25] . One MET is equivalent to the amount of oxygen consumed while in a sitting position at rest. Physical activity was then categorized as "inactive" (no reported physical activity data), "somewhat active" (<500 MET min/week) and "active" (≥500 MET min/week) [25] .
Positive smoking history was defined as self-reported current smoking or having smoked ≥100 cigarettes in one's life. Body Mass Index (BMI; kg/m 2 ) was classified as normal weight (18.5-24.9 kg/ m 2 ), overweight (25-29.9 kg/m 2 ), or obese (≥30 kg/m 2 ) on the basis of measured height and weight. Highest educational attainment was coded as less than high school, high school, or college; and, household income as <$20,000, $20,000-44,999, and ≥$45,000 [19] . Alcohol intake was considered high if an individual reported having ≥3 drinks per day [21] .
Statistical Analyses
The prevalence of MetS and its individual components, as well as the number of MetS components present (0, 1, 2, 3, 4, or 5) was determined for the U.S. adult population. The prevalence of MetS among individuals with breast, prostate, colon, and "any" cancer group was also estimated. Mean and standard error (for continuous variables), and percentage and percent standard error (for categorical variables) were determined according to MetS status. Differences in the demographic and behavioural characteristics of participants with and without MetS were assessed by independent t-tests and χ2 analyses, as appropriate.
Logistic regression was used to estimate the crude, age, and multivariable adjusted (with and without age) odds ratios (OR) and 95% Confidence Intervals (CI) for the relationship between MetS (overall, individual components, and total number of components) and any-site, breast, prostate and colon cancers. Using a linear trend analysis, the relationship between number of MetS components and cancer history was subsequently assessed. All analyses were weighted to be representative of the U.S. adult population using SAS v9.3 (Cary, NC, U.S.A). Statistical significance was set at α <0.05. The distributions of MetS and the number of MetS components in adults with a history of any-site, breast, prostate, and colon cancers are shown in Figure 2 . More than half the men and women with anysite cancer had MetS (Figure 2a ), with higher prevalences in older (vs. younger) adults (Figure 2b) . In persons with a history of any-site and site-specific cancers, generally those with 2 or 3 MetS components had the highest prevalence of any-site, prostate, post-menopausal and total breast cancers (Figure 2c, 2d ). Due to a small sample size, only pooled analyses were presented for colon cancer, prostate cancer was limited to men, and breast cancer was limited to women. Consequently, the prevalences of MetS were 57.5 ± 3.0% and 68.1 ± 4.1% in those with prostate and colon cancers, respectively.
Results
In the >50 y age group, the prevalence of any-site cancer in the subpopulation with MetS was 17.6 ± 0.8%. This prevalence ranged between 15.7-19.6%, depending on the number of MetS components and was highest in those with all 5 criteria (12.1% for men, 17.3% for women, and 4.7% for ≤ 50 years old) (data not shown). Although there was a linear-dose response relationship between the number of MetS components and cancer, the relationship was no longer significant after adjusting for covariates. The only remaining linear trend was for breast cancer, which must be interpreted with caution due to a small sample across the number of MetS components.
To explore age-differences in the above relationships, analyses were stratified by age (18-50 y vs. > 50 y). After stratification, the only remaining significant associations were for number of MetS components with prostate and colon cancer ( Table 3 ).
Discussion
Our aim was to quantify the associations between the number and composition of MetS clusters and any-site, breast, prostate and colon cancers. In general, we found that individuals with MetS had higher prevalences of any-site, breast, prostate, and colon cancers. However, after adjustment for confounders, these relationships were no longer significant. Similarly, despite a graded dose-response relationship for the number of MetS components and prevalence of site-specific cancers, no consistent associations remained after multivariable adjustment.
Our estimation of MetS prevalence is slightly higher than other studies (38% vs. 34%) using similar data and definition, a finding that may be attributed in part to our exclusion of participants with any missing MetS components, and variation in NHANES data cycles [1, 2] . MetS prevalence increases gradually with time, and since we used newer data, this may further explain our modestly higher prevalence [26] . Nonetheless, cancer prevalence in our study (any-site: 8.96%; breast: 1.22%; prostate: 0.94%; and colon: 0.43%) is similar to previous estimates, with slight variation owing to differences in sample selection criteria [27] .
MetS Components and Site-Specific Cancer
The above notwithstanding, our finding of no association between MetS and site-specific cancers is at odds with some, but not all previous work. For breast cancer, our finding of no significant association with further stratification by age and menopausal status (i.e., >50 y) is in contrast to the finding of elevated risk amongst those with MetS (1.58, 1.07-2.33) or its individual components (1.67, 1.06-2.63) reported elsewhere. On the other hand, null associations between diabetes, hypertension and dyslipidemia and breast cancer are not entirely unexpected, and have been found in other studies [10, 18, 21, 28] . Variations in the multivariable model, selection criteria, innate characteristics of the study population and study design may account for some of the observed inconsistencies.
The relationship between MetS and prostate cancer also yielded inconsistent results. In our study, low HDL was associated with 36% lower odds of prostate cancer. By contrast, a hospital-based case control by Magura [29] . Two other studies using cohort designs have produced null associations [20, 30] . Although we report a positive association between high blood glucose and prostate cancer, null and negative associations amongst older men and certain ethnic groups (RR: 0.65 [95% CI: 0.50-0.84] for European Americans, RR: 0.89 [95% CI: 0.77-1.03] for African Americans) have also been found [12, 20, 31] .
Differences in blood glucose level (i.e., high glucose (≥5.6 mM) vs. diabetes (≥11.1 mM)) may have exaggerated these differences, as only 22 of 204 prostate cancer cases had physician diagnosed diabetes in our study. Given the central role of obesity in MetS and its high prevalence in the US population, it is also possible that duration of obesity (or elevated blood glucose) may be an important factor in prostate cancer development through oxidative stress induced cell proliferation, reduced adiponectin levels, and hyperinsulinemia induced prostate/ colon cancer cell proliferation [3, 4, 32, 33] . When taken together, the discrepancy between the findings may be due to variation in: i) confounding variables and sample (i.e. hospital-based vs. nationally representative); ii) classification of past and current smokers; and iii) multivariable adjustment.
Number of MetS Components and Cancer
Studies evaluating the linear dose-response relationship between the number of MetS components and colorectal, colon, prostate, and postmenopausal breast cancers have found mixed results [17] [18] [19] [20] [21] [22] . Contrary to some but not all studies, our linear trends were generally insignificant. Despite pooling multiple cycles of NHANES, the sample size available to explore the dose-response relationship between sitespecific cancers and number of MetS components was small, and results must be interpreted with caution [17, 18, 20, 21] .
Once more, while the general pattern crude analyses was suggestive of a relationship between number of MetS clusters and any-site cancer, these associations were almost entirely reversed by age, a phenomenon known as Simpson's paradox [34] [35] [36] . Cancer risk progressively increases with age and may be linked to age-related increases in susceptibility to carcinogens, hormonal imbalance, immunologic dysfunction, and decreased capacity for cell repair/apoptosis [37] . Although several experimental studies have reported the Simpson's paradox of age, we are not aware of any population-based study that has reported the Simpson's paradox of age between cancer and MetS or its composition. Furthermore, since our results suggest that age is on the causal pathway between metabolic dysfunction and cancer, it is not a genuine confounder [34, 38] . Taken together, these findings reinforce therapeutic and preventive strategies targeting age-related causal mechanisms such as immunological decline [39] .
Limitations
First, given that our analysis is limited to cross-sectional data, cause and effect cannot be inferred. Second, because only cancer survivors are included, results may be an underestimate of the true association between MetS and cancer [40] . Finally, it is possible that changes in behaviour (consequent to cancer diagnosis) and the self-reported nature of lifestyle factors and cancer history may have also contributed to a lack of observed associations.
Conclusions
Significant crude association between the number (or composition) of MetS clusters and any-site, breast, prostate, and colon cancers are present, but accounting for age alone attenuated most of the associations. In light of the strong effect of age on these associations, additional prospective studies are needed to explore the effects of MetS components on the development and prognosis of obesity-related cancers.
